Cyclophosphamide + Cyclosporine + Etoposide + Methylprednisolone

Based on the search results, this appears to be a combination therapy used in certain medical conditions, particularly in the treatment of hemophagocytic lymphohistiocytosis (HLH). ## Drug Components **Cyclophosphamide** is an alkylating agent used in chemotherapy regimens for various cancers and autoimmune conditions. It's frequently included in combination therapies like CEPP, CEOP, and EPOCH. **Cyclosporine A** is an immunosuppressant that inhibits T-cell activation and is commonly used to prevent organ rejection after transplantation and to treat autoimmune disorders. **Etoposide** (also called VP-16) is a topoisomerase inhibitor used in various chemotherapy regimens. It's often administered at different dosages depending on the condition being treated. **Methylprednisolone** is a corticosteroid with anti-inflammatory and immunosuppressive properties. It's used to treat inflammation and immune reactions across various organ systems. ## Clinical Application This specific combination was mentioned in the management of secondary hemophagocytic lymphohistiocytosis (HLH) complicated with systemic lupus erythematosus (SLE) and chronic coronavirus infection. In the case described, the patient received: - Methylprednisolone succinate 40 mg IV daily - Cyclosporine A - Cyclophosphamide - Etoposide 100 mg twice weekly (for a limited course of 3 sessions) The administration of this combination, particularly the addition of etoposide, led to significant improvements in various indicators of HLH, including decreased levels of ferritin, lactate dehydrogenase, IL-2 receptor, IL-10, and TNF-α. This combination appears to be a tailored approach rather than a standard regimen with an established acronym like CHOP or EPOCH. It represents a multi-targeted strategy to address the hyperinflammatory state characteristic of HLH.